Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal — Live Feedhttps://www.live-feeds.com/feed/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goalContinuously updated, source-cited coverage. Novartis Shares Drop After Pelacarsen Trial Failshttps://www.live-feeds.com/feed/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goalhttps://www.live-feeds.com/feed/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal#u61414Tue, 08 Sep 2026 12:50:12 +0000Novartis shares fell more than three percent on Monday after the drugmaker announced that its experimental cardiovascular treatment pelacarsen missed the primary endpoint in a late-stage clinical trial. The Lp(a)HORIZON study enrolled more than 8,000 patients with elevated levels of lipoprotein(a) of 70mg/dL or above. While the trial assessed four-point major adverse cardiovascular events, it failed to demonstrate a reduction in the risk of heart attacks, strokes, and other serious cardiovascular events. The failure deals a blow to a treatment investors viewed as a potential blockbuster.Why it Novartis and Ionis Cholesterol Drug Fails Phase 3 Trialhttps://www.live-feeds.com/feed/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goalhttps://www.live-feeds.com/feed/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal#u58820Sun, 06 Sep 2026 08:40:13 +0000An experimental heart disease drug developed by Novartis and Ionis Pharmaceuticals failed to meet its primary goal in a late-stage clinical study. The Phase 3 trial evaluated pelacarsen in patients with elevated lipoprotein(a) levels and established cardiovascular disease. Although the treatment successfully lowered Lp(a) protein particle levels, it did not protect heart health or lower overall cardiovascular risk. The negative outcome shocked cardiologists and caused stock prices for Novartis, Ionis, and industry peers to drop after-hours. The unexpected trial failure raises significant quest